Bioperfectus Demonstrates Nucleic Acid Extraction Solutions at AACC 2021
By LabMedica International staff writers Posted on 29 Sep 2021 |
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) demonstrated its range of nucleic acid extraction solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.
The event brought together 20,000 of the sharpest minds in clinical laboratory medicine for four science packed days. At the conference, attendees heard from the foremost experts on topics from personalized medicine and infectious diseases to point-of-care and laboratory-developed tests. At the Clinical Lab Expo, attendees evaluated hundreds of new technologies just coming to market that can enhance their lab.
At AACC 2021, Bioperfectus showcased its new SMPE-960 nucleic acid extraction system which is an in vitro diagnostic medical device that integrates cutting-edge mechanical, electronic and software technologies to enable automated extraction of nucleic acids from samples with a modular structure - the equipment can extract nucleic acids from 1-96 samples in three independently operating modules at the same time. Each module consists of 1-32 samples so that samples can be tested upon delivery.
Bioperfectus also displayed its Nucleic Acid Extraction Rapid Kit (Magnetic Bead Method) which uses magnetic beads and a buffer system with unique separation function. The kit is used in conjunction with the SMPE-960 nucleic acid extraction system to separate and purify high-quality viral nucleic acids from samples. The specially coated magnetic beads have a strong affinity for the nucleic acid in the sample under certain conditions. When the conditions change, the magnetic beads release the adsorbed nucleic acid, so that the nucleic acid in the purified sample can be quickly extracted. This kit is used for the extraction and purification of viral nucleic acids (DNA and RNA) from samples such as serum, plasma, virus culture fluid, cerebrospinal fluid, urine, swab wash, fecal supernatant, etc. The purified nucleic acid can be used in downstream molecular biology experiment.
Also on display at the event was the COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit from Bioperfectus that is an In Vitro Diagnostic (IVD) reagent relying on fluorescent PCR technology and aiming at qualitatively detection and differentiation of human RNA from SARS-CoV-2 from upper and lower respiratory tract samples. Primer and probe are selected from Open Reading Frame gene region (ORF1a/b), envelope protein (E) and nucleocapsid region (N) for SARS-CoV-2. The kit is a multiplex assay, run in a single well/vessel, designed for detection and differentiation of RNA from SARS-CoV-2. In addition, the kit also contains human house-keeping gene (RNase P) for clinical sample detection. The product is intended for use on populations suspected to have SARS-CoV-2 infection, as an aid in the diagnosis of SARS-CoV-2 infection by trained laboratory personnel on RT-PCR.
In addition, Bioperfectus highlighted its Viral Nucleic Acid Extraction Kit (Magnetic Bead Method) which uses magnetic beads and a buffer system with unique separation function. The kit is used in conjunction with the SMPE-960 nucleic acid extraction system to separate and purify high-quality viral nucleic acids from samples. The specially coated magnetic beads have a strong affinity for the nucleic acid in the sample under certain conditions. When the conditions change, the magnetic beads release the adsorbed nucleic acid, so that the nucleic acid in the purified sample can be quickly extracted. This kit is used for the extraction and purification of viral nucleic acids (DNA and RNA) from samples such as serum, plasma, virus culture fluid, cerebrospinal fluid, urine, swab wash, fecal supernatant, etc. The purified nucleic acid can be used in a downstream molecular biology experiment.
Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms